香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Perfect Optronics Limited 圓美光電有限公司 （於開曼群島註冊成立之有限公司） 1. 考慮及批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期未 經審核綜合業績及批准將於香港聯合交易所有限公司GEM（「GEM」）及本公司 網站刊登有關之公告；及 2. 處理任何其他事項。 （股份代號：8311） 董事會會議通告 圓美光電有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於二零二五年 八月二十九日舉行董事會會議，以便處理下列事項： 代表董事會 圓美光電有限公司 代理主席 簡文偉 香港，二零二五年八月十九日 於本公告日期，董事會包括四名執行董事，即鄭偉德先生（已暫停職務）、廖嘉榮先 生（已暫停職務）、謝家榮先生（已暫停職務）及張桓嘉先生；和三名獨立非執行董 事，即簡文偉先生（代理主席）、徐慧敏女士及劉毅基先生。 本公告的資料乃遵照《香港聯合交易所有限公司的GEM證券上 ...

公告称，转盈为亏主要由于本期间预期取得集团按公允价值计入损益的金融资产的公允价值亏损约706 万港元，相比2024年同期的公允价值收益约1508.2万港元。该集团按公允价值计入损益的金融资产为集 团持有的若干出门问问有限公司于香港联合交易所有限公司上市的普通股份(股份代号：2438)，其公允 价值乃参照出门问问的普通股份市值而估算。尽管本期间集团业务营运所产生的亏损与2024年同期相应 的集团业务营运所产生的亏损相比有所减少，上述集团按公允价值计入损益的金融资产的公允价值亏损 预期导致本期间由盈转亏。 圆美光电(08311)公布，预期2025年上半年该集团财务业绩将转盈为亏，取得公司权益持有人应占综合 亏损约1200万港元至1400万港元，2024年上半年公司权益持有人应占综合利润约225万港元。 ...

智通财经APP讯，圆美光电(08311)公布，预期2025年上半年该集团财务业绩将转盈为亏，取得公司权益 持有人应占综合亏损约1200万港元至1400万港元，2024年上半年公司权益持有人应占综合利润约225万 港元。 公告称，转盈为亏主要由于本期间预期取得集团按公允价值计入损益的金融资产的公允价值亏损约706 万港元，相比2024年同期的公允价值收益约1508.2万港元。该集团按公允价值计入损益的金融资产为集 团持有的若干出门问问有限公司于香港联合交易所有限公司上市的普通股份(股份代号：2438)，其公允 价值乃参照出门问问的普通股份市值而估算。尽管本期间集团业务营运所产生的亏损与2024年同期相应 的集团业务营运所产生的亏损相比有所减少，上述集团按公允价值计入损益的金融资产的公允价值亏损 预期导致本期间由盈转亏。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Perfect Optronics Limited 盈利警告 本公告由圓美光電有限公司（「本公司」，連同其附屬公司，統稱「本集團」）根據《香 港聯合交易所有限公司的GEM證券上市規則》（「GEM上市規則」）第17.10條及證券 及期貨條例（香港法例第571章）第XIVA部項下之內幕消息條文（定義見GEM上市 規則）而作出。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，根據對本集 團未經審核綜合管理賬目之初步評估，預期截至二零二五年六月三十日止六個月 （「本期間」）的本集團財務業績將轉盈為虧，錄得本公司權益持有人應佔綜合虧損介 乎約12,000,000港元至14,000,000港元，相比截至二零二四年六月三十日止六個月 之本公司權益持有人應佔綜合利潤約2,250,000港元。 上述預期本期間之轉盈為虧主要由於本期間預期錄得本集團按公允價值計入損益 （「按公允價值計入損益」）之金融資 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 圓美光電有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08311 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | 50,000,000 | 本月底 ...

Financial Performance - The Group's revenue decreased by 25% from approximately HK$124,255,000 in 2023 to approximately HK$92,605,000 in 2024[20]. - Loss attributable to equity holders of the Company for the Year amounted to approximately HK$42,906,000, an increase of approximately HK$23,802,000 compared to HK$19,104,000 in 2023[20]. - The Group recognized a fair value loss on its financial asset at fair value through profit or loss of approximately HK$19,207,000 during the Year, compared to a fair value gain of approximately HK$10,647,000 in 2023[20]. - The financial results reflect prolonged pressure due to adverse market conditions and strategic challenges faced by the Group[20]. - The Group's total revenue for the year amounted to approximately HK$92,605,000, representing a 25% decrease compared to approximately HK$124,255,000 in 2023[44][50]. - Gross profit for the year was approximately HK$10,654,000, down by approximately HK$4,640,000 from approximately HK$15,294,000 in 2023, mainly due to the decline in revenue[52]. - The Group recorded net other losses of approximately HK$18,818,000, compared to net other gains of approximately HK$10,956,000 in 2023, largely due to a fair value loss of approximately HK$19,207,000 on the investment in Mobvoi[53]. Sales Performance - Sales of TFT-LCD panels and modules dropped approximately 52%, from HK$83,992,000 in 2023 to approximately HK$40,161,000[23]. - Sales of electronic signage products decreased by approximately 7%, from HK$14,029,000 in 2023 to approximately HK$12,997,000[24]. - Sales of optics products increased significantly to approximately HK$25,594,000, up approximately HK$20,600,000 from HK$4,994,000 in 2023[25]. - Sales of health-related products fell by approximately 30%, from HK$18,209,000 in 2023 to approximately HK$12,799,000[28]. - The decline in sales of electronic signage was mainly attributed to decreased demand in the education sector[24]. Market Conditions - The global display panel market faced challenges from supply and demand imbalance and changes in market demand, impacting the Group's financial results[20]. - Demand for pandemic-related hygiene products continued to decline in the post-pandemic era, further affecting the Group's performance[20]. - The Group anticipates facing challenges due to global economic uncertainty, geopolitical tensions, and trade frictions, and will adjust business strategies accordingly[33][36]. Strategic Initiatives - The Group is engaged in trading, development, and sales of display and optics products, as well as health-related products[19]. - The Company aims to navigate the complex market environment and explore new opportunities for growth in the future[20]. - The Group's strategy includes expanding its product portfolio to include rapid antigen test kits and health supplements in response to market changes[28]. - The Group strategically entered the pet-care market, launching a series of pet health food products during the year[28]. - The Group aims to explore new market opportunities and strengthen relationships with suppliers and customers to create greater shareholder value[33][36]. Cost Management - The cost of sales decreased to approximately HK$81,951,000, a 25% reduction from approximately HK$108,961,000 in 2023, primarily due to decreased sales of TFT-LCD panels and health-related products[51]. - Distribution and selling expenses decreased by approximately 43% to approximately HK$12,533,000 from approximately HK$22,087,000 in 2023, attributed to lower staff costs and promotion expenses[54]. - General and administrative expenses amounted to approximately HK$21,557,000, representing a 10% decrease from approximately HK$23,890,000 in 2023, mainly due to reduced staff costs[55]. - Research and development expenses increased by approximately 31% to approximately HK$1,227,000 from approximately HK$938,000 in 2023, driven by higher staff costs[56]. Cash Flow and Assets - Cash and cash equivalents decreased by approximately 48% to HK$24,407,000 from HK$47,372,000 in 2023[70]. - Total assets decreased by approximately 50% to HK$58,357,000 from HK$116,131,000 in 2023[69]. - The Group's net current assets position was HK$41,117,000 as of December 31, 2024, compared to HK$50,301,000 in 2023, indicating a decline of 18.2%[75]. - The Group's total bank borrowings as of December 31, 2024, were approximately HK$3,809,000, down 15.7% from HK$4,519,000 in 2023[72]. Corporate Governance - The Company has complied with all code provisions of the Corporate Governance Code during the year[120]. - The Board of Directors consists of four executive Directors and three independent non-executive Directors as of the date of the annual report[122]. - The Company is committed to high standards of corporate governance to protect shareholder interests[125]. - The audit committee held three meetings during the Year, reviewing the Company's annual financial statements and internal control systems[159]. - The Company has received annual independence confirmation from each of the existing independent non-executive Directors, affirming their independence[151]. Employee and Gender Diversity - The employee headcount decreased to 53 as of December 31, 2024, from 67 in 2023, reflecting a reduction of 20.9%[80]. - Total staff costs, including directors' emoluments, were approximately HK$22,595,000 for the year, down 8.6% from HK$24,713,000 in 2023[80]. - The employee gender ratio of the Group is 30 males to 23 females, reflecting the Group's commitment to gender diversity[196]. - The nomination committee has deemed the existing Diversity Policy suitable and effective after review during the year[200].

Financial Performance - The company reported a revenue of HKD 92,605,000 for the year ending December 31, 2024, a decrease of 25.6% compared to HKD 124,255,000 in 2023[3]. - Gross profit for the year was HKD 10,654,000, down 30.5% from HKD 15,294,000 in the previous year[3]. - The operating loss increased to HKD 43,481,000, compared to a loss of HKD 20,665,000 in 2023, indicating a significant decline in operational performance[3]. - The net loss for the year was HKD 43,641,000, which is a 110.5% increase from the net loss of HKD 20,720,000 in the prior year[3]. - The group reported a loss attributable to equity holders of HKD 42,906,000 for the year 2024, compared to a loss of HKD 19,104,000 in 2023, resulting in a basic and diluted loss per share of HKD 2.89[25]. - The loss attributable to equity holders of the company increased to approximately HKD 42,906,000, up from approximately HKD 19,104,000 in the previous year, representing an increase in loss of about HKD 23,802,000[33]. - Other net losses for the year amounted to approximately HKD 18,818,000, compared to other net income of approximately HKD 10,956,000 in 2023[41]. Assets and Liabilities - The company's total assets decreased to HKD 58,357,000 from HKD 116,131,000 in 2023, reflecting a 49.8% decline[4]. - Cash and cash equivalents fell to HKD 24,407,000, down 48.6% from HKD 47,372,000 in the previous year[4]. - The company’s net current assets were HKD 41,117,000, a decrease of 18.2% from HKD 50,301,000 in 2023[9]. - Non-current assets as of December 31, 2024, totaled HKD 6,010,000, compared to HKD 5,491,000 as of December 31, 2023[18]. - The company's accounts receivable decreased from HKD 7,944,000 in 2023 to HKD 4,871,000 in 2024[28]. - Accounts payable decreased significantly from HKD 19,034,000 in 2023 to HKD 8,250,000 in 2024[29]. - The company's capital debt ratio as of December 31, 2024, was 8.4%, compared to 5.1% in 2023[48]. Revenue Breakdown - The group's revenue from major products for the year ended December 31, 2024, was HKD 92,605,000, a decrease of 25.5% from HKD 124,255,000 in 2023[16]. - The revenue from TFT-LCD panels and modules was HKD 40,161,000, down 52.2% from HKD 83,992,000 in the previous year[16]. - Sales revenue from TFT-LCD panels and modules was approximately HKD 40,161,000, a decline of about 52% from approximately HKD 83,992,000 in 2023[34]. - Sales revenue from electronic advertising products was approximately HKD 12,997,000, down about 7% from approximately HKD 14,029,000 in 2023[34]. - Sales revenue from optical products increased to approximately HKD 25,594,000, up about HKD 20,600,000 from approximately HKD 4,994,000 in 2023[35]. - Sales revenue from health-related products was approximately HKD 12,799,000, a decrease of about 30% from approximately HKD 18,209,000 in 2023[35]. Cost Management and Future Plans - The company plans to implement cost control measures, including adjustments to human resources and streamlining other operating expenses[10]. - The group plans to enhance cash flow and working capital by adjusting sales activities and deferring discretionary capital expenditures if necessary[14]. - The group's operating expenses control measures are aimed at improving cash flow, with a focus on reducing costs and enhancing sales[14]. Going Concern and Uncertainties - The board has expressed significant uncertainty regarding the company's ability to continue as a going concern due to ongoing losses and market challenges[9]. - The board believes that the group will have sufficient financial resources to meet its financial obligations for at least the next twelve months from December 31, 2024[11]. Dividends and Shareholder Information - The group did not declare any dividends for the current year, consistent with the previous year[26]. - The board of directors does not recommend or declare any dividends for the year (2023: none) [52]. - The company has not declared any dividends since its investment in Outermost Technology in January 2015[27]. Legal and Governance Matters - The company is currently involved in legal proceedings initiated by the Securities and Futures Commission regarding alleged breaches of duties by certain directors[54]. - The company has adopted the principles and code provisions of the Corporate Governance Code as per GEM Listing Rules Appendix C1[56]. - The audit committee, established on January 20, 2014, consists of three independent non-executive directors and has reviewed the annual audited results[58]. - The company's auditor, PwC, confirmed that the figures in the preliminary results announcement are consistent with the audited financial statements[59]. Meeting and Share Transfer Information - The annual general meeting is scheduled for June 12, 2025, with a suspension of share transfer registration from June 9 to June 12, 2025[60][61].

Financial Performance - For the six months ended June 30, 2024, the group recorded revenue of approximately HKD 52.5 million, a decrease of 21.1% compared to HKD 66.5 million for the same period in 2023[7]. - The profit attributable to equity holders for the six months ended June 30, 2024, was approximately HKD 2.3 million, a significant improvement from a loss of HKD 3.9 million in the same period of 2023[7]. - Gross profit for the six months ended June 30, 2024, was HKD 6.5 million, compared to HKD 10.1 million for the same period in 2023, reflecting a gross margin decrease[8]. - Operating profit for the six months ended June 30, 2024, was HKD 1.9 million, a turnaround from an operating loss of HKD 4.5 million in the same period of 2023[8]. - Total comprehensive income for the six months ended June 30, 2024, amounted to HKD 1.98 million, compared to a loss of HKD 4.1 million in the same period of 2023[9]. - The basic and diluted earnings per share for the six months ended June 30, 2024, was HKD 0.15, compared to a loss per share of HKD 0.26 in the same period of 2023[9]. - The group reported a profit attributable to equity holders of HKD 2,250 for the six months ended June 30, 2024, compared to a loss of HKD 3,859 in the same period of 2023[39]. - Basic and diluted earnings per share for the six months ended June 30, 2024, were HKD 0.15, recovering from a loss of HKD 0.26 in 2023[39]. Revenue Breakdown - Revenue from the company's main products for the six months ended June 30, 2024, totaled HKD 21,372,000 for TFT-LCD panels and modules, compared to HKD 16,176,000 for the same period in 2023, indicating a growth of 32.5%[29]. - Total revenue from electronic billboards reached HKD 7,332,000, an increase from HKD 5,023,000 year-over-year, representing a growth of 46.0%[29]. - Health-related product revenue decreased to HKD 6,884,000 from HKD 11,913,000, reflecting a decline of 42.1%[29]. - Revenue from external customers in Hong Kong was HKD 46,991,000, down from HKD 60,259,000, a decrease of 22.0%[30]. - The company's revenue from mainland China dropped to HKD 3,208,000 from HKD 5,888,000, a decline of 45.5%[30]. Cash Flow and Assets - As of June 30, 2024, total assets were HKD 115.8 million, slightly down from HKD 116.1 million as of December 31, 2023[10]. - The company's cash and cash equivalents decreased to HKD 37.2 million from HKD 47.4 million as of December 31, 2023[10]. - The total financial assets as of June 30, 2024, amounted to HKD 96,528 thousand, up from HKD 91,118 thousand as of December 31, 2023, reflecting a 5.5% increase[17]. - The company reported a net cash used in investing activities of HKD (563) thousand for the six months ended June 30, 2024, compared to a net cash generated of HKD 100 thousand in the same period of 2023[13]. - The company’s cash flow from financing activities was HKD (1,962) thousand for the six months ended June 30, 2024, compared to HKD (2,457) thousand in the same period of 2023, indicating a 20.2% improvement[13]. Liabilities and Equity - Total liabilities decreased to HKD 25.0 million as of June 30, 2024, from HKD 27.4 million as of December 31, 2023[11]. - The total liabilities decreased from HKD 23,067 thousand as of December 31, 2023, to HKD 22,220 thousand as of June 30, 2024, showing a reduction of 3.7%[17]. - The company’s bank loans decreased slightly from HKD 4,519 thousand to HKD 4,168 thousand, a decline of 7.7%[17]. - The company’s lease liabilities decreased from HKD 3,407 thousand to HKD 2,300 thousand, representing a significant reduction of 32.5%[17]. - The group’s debt-to-equity ratio as of June 30, 2024, was 4.6%, down from 5.1% as of December 31, 2023[65]. Shareholder Information - As of June 30, 2024, Mr. Zheng Weide holds 923,427,151 shares through Winful Enterprises, representing 62.24% of the company's issued shares[77]. - Mr. Zheng Weide is also the beneficial owner of an additional 2,220,000 shares, bringing his total ownership to 925,647,151 shares, or 62.39%[77]. - The company has a stock option plan with 132,000,000 options available as of January 1, 2024, which expired on January 19, 2024[81]. - The new stock option plan approved on June 18, 2024, allows for 148,368,715 options to be granted[81]. - The company did not repurchase any shares during the reporting period, nor did it buy or sell any of its shares[83]. Corporate Governance - The company has adopted a code of conduct for directors regarding securities trading, ensuring compliance with GEM listing rules[84]. - The company has established a non-competition agreement with its controlling shareholder, Mr. Zheng Weide, to prevent competition with its existing business activities[85]. - The company has adopted the principles and code provisions of the corporate governance code as per GEM Listing Rules Appendix C1 and has complied with all code provisions during the reporting period[90]. - There has been a change in the board of directors, with Mr. Cao Zhiguang resigning as an independent non-executive director effective July 1, 2024, and Mr. Liu Yiji appointed as his replacement[91]. - The company has established an audit committee consisting of three independent non-executive directors, with Ms. Xu Huimin serving as the chairperson[92]. Legal Matters - The company is currently involved in legal proceedings initiated by the Securities and Futures Commission regarding the sale of approximately 50.14% of its subsidiary's shares[88]. - As of September 25, 2020, the directors involved in the legal proceedings have suspended their duties, including the Chairman and CEO[88].

Financial Performance - Total revenue for Perfect Optronics Limited in 2023 amounted to approximately HK$124.3 million, representing a 59% decrease compared to 2022[21]. - Loss attributable to equity holders of the Company for the Year amounted to approximately HK$19.1 million, compared to a profit of approximately HK$4.0 million in 2022[21]. - The Group's total revenue for the year was approximately HK$124.3 million, representing a significant decrease of 59% compared to approximately HK$301.3 million in 2022[24][34]. - The Group recorded a loss attributable to equity holders of approximately HK$19.1 million for the year, compared to a profit of approximately HK$4.0 million in 2022[24][34]. - Gross profit for the Group was approximately HK$15,294,000, down by approximately HK$54,375,000 compared to approximately HK$69,669,000 in 2022[68]. - Revenue for the year was HK$124,255,000, representing a decrease of 59% from HK$301,318,000 in 2022[87]. - Gross profit decreased by 78% to HK$15,294,000, with a gross profit margin of 12.3%, down from 23.1% in 2022[87]. - Total cost of sales for the Group was approximately HK$108,961,000, a decrease of approximately 53% from approximately HK$231,649,000 in 2022[67]. Sales Performance - Sales of health-related products, including COVID-19 rapid antigen test kits, decreased significantly from approximately HK$87.9 million in 2022 to approximately HK$18.2 million in 2023[19]. - Sales of thin film transistor liquid crystal display (TFT-LCD) panels and modules dropped from approximately HK$155.9 million in 2022 to approximately HK$84.0 million in 2023[20]. - The decline in sales was attributed to reduced demand for display products and health-related items due to the easing of the COVID-19 pandemic[19][20]. - Sales of health-related products dropped sharply from approximately HK$87.9 million in 2022 to about HK$18.2 million in the current year[23]. - Sales of TFT-LCD panels and modules decreased from approximately HK$155.9 million in 2022 to about HK$84.0 million in the current year[23]. - Sales of polarisers dropped significantly by approximately 98%, totaling approximately HK$782,000 compared to HK$36,554,000 in 2022[38]. - Revenue from electronic signage products decreased by approximately 14%, reaching approximately HK$14,029,000 compared to HK$16,396,000 in 2022[39]. - Sales of optics products increased significantly by approximately HK$4,404,000, totaling approximately HK$4,994,000 compared to HK$590,000 in 2022[40]. - Sales of health-related products fell by approximately 79%, amounting to approximately HK$18,209,000 compared to HK$87,876,000 in 2022[44]. Investment and Fair Value - The Group recorded a fair value gain on its investment in Mobvoi Inc. of approximately HK$10.6 million, which was offset by the significant decrease in revenue[21]. - The Group recognized a fair value gain of approximately HK$10.6 million on its investment in Mobvoi during the year[24][26]. - The fair value of the Group's investment in Mobvoi increased by approximately 42%, reaching approximately HK$35,848,000 as of December 31, 2023, compared to HK$25,201,000 in 2022[45]. - The Group's investment in Mobvoi, classified as a financial asset at fair value through profit or loss, had a fair value of approximately HK$35,848,000 as of December 31, 2023, representing about 30.9% of the Group's total assets[122]. - A fair value gain of approximately HK$10,647,000 was recognized on the investment in Mobvoi during the year[122]. Strategic Initiatives - The Group introduced new health-related products, such as supplements, to diversify its product portfolio in response to changing market demands[22]. - The Group's strategy includes continuing to diversify its product offerings to adapt to market changes and consumer health awareness[22]. - The Group is expanding its product portfolio by launching health-related products to leverage increased health awareness post-pandemic[24][29]. - The Group plans to pursue a diversified business strategy to navigate ongoing challenges posed by the global economic environment[27][30]. - The Group plans to explore product diversity and new business opportunities to adapt to market challenges and ensure stability[50]. Economic and Market Conditions - The sluggish display panels market and global inflation significantly affected the Group's sales performance[20]. - The Group's financial performance may be adversely affected by a slowdown in the global economy and reduced market demand[51]. - The Group's inventory risk is heightened due to potential obsolescence as technology evolves quickly[56]. Corporate Governance - The Company has complied with all code provisions of the Corporate Governance Code during the Year[138]. - The Board comprises four executive Directors and five independent non-executive Directors, with several Directors currently suspended[140]. - The management is responsible for implementing strategies and reporting on the Group's operations to the Board regularly[148]. - The Company has arranged appropriate insurance coverage for Directors' and officers' liabilities, reviewed annually[150]. - All minutes of the Board meetings were recorded in sufficient detail regarding matters considered and decisions made[151]. - The Company held four regular board meetings during the year, with all directors attending all meetings[157]. - The Company has appointed five independent non-executive directors, representing more than one-third of the Board, ensuring compliance with GEM Listing Rules[170]. - The audit committee consists of three independent non-executive directors, with Ms. Hsu Wai Man Helen serving as chairperson, possessing appropriate accounting expertise[172]. - The Company has established three Board committees: audit committee, remuneration committee, and nomination committee, to oversee specific aspects of the Company's affairs[171]. - The Company provides sufficient resources to its Board committees to effectively discharge their duties[171]. Legal and Compliance Matters - The legal proceedings involving certain Directors are ongoing, with allegations of breach of duties related to a subsidiary holding approximately 50.14% of Shinyoptics Corporation[130]. - The Director Respondents have been suspended from their duties since September 25, 2020, pending the outcome of the legal proceedings[131]. - The Company has received annual independence confirmation from each independent non-executive director, affirming their independence as per GEM Listing Rules[170]. Financial Position - Cash and cash equivalents decreased by 45% to approximately HK$47,372,000 from HK$85,709,000 in 2022[91]. - Total assets decreased by 24% to HK$116,131,000 from HK$153,750,000 in 2022[90]. - Total liabilities decreased by 38% to HK$27,355,000 from HK$44,412,000 in 2022[90]. - The current ratio increased to 3.2 times from 3.0 times in 2022, while the quick ratio decreased to 2.4 times from 2.5 times[90]. - Bank borrowings decreased to approximately HK$4,519,000 from HK$5,206,000 in 2022[92]. - The Group's total staff costs for the year were approximately HK$24,713,000, down from HK$26,495,000 in 2022, with an employee headcount of 67 as of December 31, 2023, compared to 65 in 2022[101].

Financial Performance - For the fiscal year ending December 31, 2023, the company's revenue was approximately HKD 124.3 million, a decrease of about 59% compared to HKD 301.3 million in 2022[7] - The company reported a loss attributable to equity holders of approximately HKD 19.1 million for the year, compared to a profit of HKD 4.0 million in 2022[7] - The company incurred operating losses of HKD 20.7 million for the year, compared to an operating profit of HKD 4.2 million in 2022[9] - The company’s basic and diluted loss per share was HKD 1.29, compared to earnings of HKD 0.27 per share in the previous year[9] - The revenue from the main products for the year ended December 31, 2023, was HKD 124,255 thousand, a decrease of 58.8% compared to HKD 301,318 thousand in 2022[21] - The revenue from health-related products dropped significantly to HKD 18,209 thousand in 2023 from HKD 87,876 thousand in 2022, representing a decline of 79.2%[21] - The company's revenue for the year was approximately HKD 124,255,000, a significant decrease of about 59% compared to approximately HKD 301,318,000 for the year ended December 31, 2022[46] - The gross profit for the year was approximately HKD 15,294,000, down from approximately HKD 69,669,000 in 2022, reflecting a significant decline due to reduced income from health-related products[57] - The total sales cost for the year was approximately HKD 108,961,000, a reduction of about 53% from approximately HKD 231,649,000 in 2022[56] Assets and Liabilities - The total assets as of December 31, 2023, amounted to HKD 116.1 million, down from HKD 153.8 million in 2022[11] - The total equity attributable to equity holders was HKD 92.3 million, a decrease from HKD 111.2 million in the previous year[11] - The company’s cash and cash equivalents were HKD 47.4 million, down from HKD 85.7 million in 2022[11] - The company’s total liabilities decreased to HKD 27.4 million from HKD 44.4 million in the previous year[11] - The accounts receivable decreased to HKD 7,944,000 from HKD 10,031,000 in 2022[11] - Accounts payable decreased to HKD 19,034,000 from HKD 34,464,000 in 2022[44] Dividends - The board of directors did not recommend the declaration of any final dividend for the year[7] - The company did not declare any dividends for the current year, consistent with the previous year[36] Governance and Compliance - The company has adopted the principles and code provisions of the Corporate Governance Code as per GEM Listing Rules Appendix C1, ensuring high standards of corporate governance to protect shareholder interests[75] - The company has complied with all code provisions of the Corporate Governance Code in effect during the year[76] - The Audit Committee, established on January 20, 2014, consists of three independent non-executive directors, with Ms. Xu Huimin serving as the chairperson, ensuring proper oversight of the annual audited performance[77] - The auditors, PwC, confirmed that the figures in the preliminary performance announcement align with the audited consolidated financial statements for the year ending December 31, 2023[78] Future Outlook - The company plans to explore product diversification and seek new suppliers and customers to address market challenges[53] - The company continues to explore opportunities in the health-related product market despite the decline in demand due to the easing of the COVID-19 pandemic[50] Legal Matters - The company is actively defending against the claims made by the Securities and Futures Commission, with legal proceedings ongoing as of the announcement date[74] Meeting and Shareholder Information - The company's annual general meeting is scheduled for June 18, 2024, with a notice to be published in accordance with GEM Listing Rules[79] - Share transfer registration will be suspended from June 13 to June 18, 2024, to determine voting rights at the annual general meeting[81] - The board of directors includes four executive directors and five independent non-executive directors, with several members currently suspended from their positions[82]